- Live Vaccines
- Cell free PA Vaccines
Anthrax Vaccine Market size was valued at USD x billion in 2022 and is poised to grow at a significant CAGR of 7.5% from 2023-29. Anthrax is a severe infectious disease caused by bacillus anthracis. Signs and symptoms include vomiting, nausea, abdominal pain, headache, and loss of appetite, fever, severe bloody diarrhoea in the later stages of the disease, sore throat, and difficulty swallowing. Risk factors for anthrax include injection of illegal drugs, handling animal skins, and working in veterinary medicine, especially dealing with livestock. The market is driven by growing threat of communicable diseases such as anthrax across the globe. Moreover cost-effectiveness of immunizations, new funding opportunities from government, donors, research foundations, advances in research and manufacturing technologies expected to drive market revenue growth of anthrax vaccine over a forecast period. In addition, availability of large target population in emerging markets driving the growth of the anthrax vaccines market. However, lack of awareness, the high cost of the vaccine in under developed economies, lack of availability and affordability, stringent regulations are the factors which are restraining the growth of the market. This report market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, the market report includes human demographics; regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed global market to better equip clients with possible investment opportunities across the regions (regional Investment Hot-Spots) and market unmet needs (Product Opportunities). Key stakeholders of the global market report include suppliers, manufacturers, marketers, policy makers, and service providers engaged in global Anthrax Vaccine.
Global Anthrax Vaccine Market Summary
Study Period
2023-29
Base Year
2022
CAGR
7.5%
Largest Market
North America
Fastest Growing Market
Asia Pacific
Anthrax Vaccine Market Dynamics
The growing efforts and of interest market players in expanding the product portfolio related to anthrax prevention are expected to impel the market growth over the forecast period. Growing government funding in the United States to generate and store sufficient vaccines against anthrax through various programs, such as Joint Program Executive Office for Chemical and Biological Defense, Biomedical Advanced Research and Development Authority (BARDA), BioShield Legislation and is creating market opportunities for the market players. One of the U.S. FDA-approved products against anthrax is BioThrax, manufactured by Emergent BioDefense Operations Lansing LLC, for active immunization against anthrax.
Anthrax Vaccine Market Regional Analysis
North America Got Significant Share
Geographically, global anthrax vaccine market is segmented into five key regions Viz. North America, Europe, Asia-Pacific, Latin America, and The Middle East & Africa. North America market expected to present better growth opportunities for market players owing to government initiatives to curb anthrax. The presence of various ongoing programs under the organizations such as BARDA, HHSCDC, NIAID, ASPR, and the FDA is one of the key contributing factors for the revenue generation in North America region. Asia Pacific is expected to witness a significant demand on account of surging investments in the R&D sector. The extensive vaccine manufacturing facilities across Japan coupled with the presence of sophisticated healthcare infrastructure in the country is contributing to its strong market position.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments and startup’s details that are actively working in the market
- The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
- The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
Global Anthrax Vaccine Market Segmentation
By Type
By End User
- Hospitals
- Clinics,
- Vaccination Centers
- Others
By Geography
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East and Africa
Frequently Asked Questions
2021 is the base year and 2028 is the forecast year.
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.
- Emergent BioSolutions (U.S.)
- Elusys Therapeutics (U.S.)
- Porton Biopharma Limited (U.K)
- Panacea Biotec (India)